AlphaCentric Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

AlphaCentric Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-68,500	Closed	-$354K	–	222
2021 Q3	$354K	Sell	68,500 -51,500	-43%	-$231K	0.09%	84
2021 Q2	$511K	Buy	120,000 +69,000	+135%	+$335K	0.14%	61
2021 Q1	$271K	Buy	51,000 +7,000	+16%	+$40.1K	0.09%	80
2020 Q4	$237K	Buy	44,000 +39,800	+948%	+$216K	0.1%	59
2020 Q3	$34K	Buy	4,200 +2,400	+133%	+$21K	0.02%	126
2020 Q2	$18K	Buy	+1,800	New	+$11.3K	0.01%	124

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AlphaCentric Advisors's ADAP Position: Q4 2021 in Review

AlphaCentric Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q4 2021, closing a stake of 68,500 shares — an estimated $354K sold.

AlphaCentric Advisors first reported a position in ADAP in Q2 2020 and held it in 6 quarters. The position peaked at $511K in Q2 2021. 85 funds tracked by Wall St. Rank hold ADAP as of Q4 2021.

AlphaCentric Advisors reported no remaining Adaptimmune Therapeutics position as of Q4 2021 after selling out during the quarter.
AlphaCentric Advisors sold 68,500 Adaptimmune Therapeutics shares in Q4 2021, an estimated $354K.
AlphaCentric Advisors first reported a position in Adaptimmune Therapeutics in Q2 2020 and held it in 6 quarters.
AlphaCentric Advisors's Adaptimmune Therapeutics position peaked at $511K in Q2 2021.
85 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.